About Kala Pharmaceuticals (NASDAQ:KALA)
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252
Debt
Debt-to-Equity Ratio0.13%
Current Ratio7.97%
Quick Ratio7.97%
Price-To-Earnings
Trailing P/E Ratio-2.73
Forward P/E Ratio-8.06
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales9,799.44
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book4.36
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees37
Outstanding Shares24,560,000
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals (NASDAQ:KALA) issued its quarterly earnings data on Monday, March, 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. View Kala Pharmaceuticals' Earnings History.
What price target have analysts set for KALA?
5 brokers have issued 1-year price targets for Kala Pharmaceuticals' shares. Their forecasts range from $19.00 to $46.00. On average, they expect Kala Pharmaceuticals' stock price to reach $35.80 in the next twelve months. View Analyst Ratings for Kala Pharmaceuticals.
Are investors shorting Kala Pharmaceuticals?
Kala Pharmaceuticals saw a decline in short interest in March. As of March 15th, there was short interest totalling 1,165,475 shares, a decline of 21.7% from the February 28th total of 1,488,996 shares. Based on an average daily trading volume, of 277,453 shares, the days-to-cover ratio is presently 4.2 days. Approximately 8.0% of the shares of the stock are sold short.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH) and PTC Therapeutics (PTCT).
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Exec. Chairman and Chief Exec. Officer (Age 52)
- Dr. Hongming Chen Sc.D., Chief Scientific Officer (Age 47)
- Dr. Kim Brazzell Ph.D., Chief Medical Officer (Age 65)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CFO & Treasurer (Age 43)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Has Kala Pharmaceuticals been receiving favorable news coverage?
Press coverage about KALA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave press coverage about the company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $15.96.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $392.90 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kala Pharmaceuticals (NASDAQ:KALA) Earnings History and Estimates Chart
Kala Pharmaceuticals (NASDAQ:KALA) Earnings Estimates
2018 EPS Consensus Estimate: ($2.10)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q2 2018 | 1 | ($0.52) | ($0.52) | ($0.52) |
| Q3 2018 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q4 2018 | 1 | ($0.56) | ($0.56) | ($0.56) |
Kala Pharmaceuticals (NASDAQ KALA) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/26/2018 | Q4 2017 | ($0.37) | ($0.46) | | | View | Listen |  |
| 11/7/2017 | Q3 2017 | ($0.4250) | ($0.56) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Kala Pharmaceuticals (NASDAQ:KALA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kala Pharmaceuticals (NASDAQ KALA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 72.30%
Kala Pharmaceuticals (NASDAQ KALA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/8/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 25,000 | $12.93 | $323,250.00 | | |
| 2/1/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 362,240 | $15.00 | $5,433,600.00 | | |
| 1/29/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 72,760 | $14.97 | $1,089,217.20 | | |
| 1/26/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 22,760 | $14.93 | $339,806.80 | | |
| 1/24/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 64,637 | $14.91 | $963,737.67 | | |
| 1/22/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 75,000 | $14.98 | $1,123,500.00 | | |
| 1/19/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 74,931 | $14.95 | $1,120,218.45 | | |
| 1/12/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 240,484 | $13.28 | $3,193,627.52 | | |
| 1/10/2018 | Orbimed Advisors Llc | Major Shareholder | Buy | 170,338 | $12.83 | $2,185,436.54 | | |
| 7/25/2017 | Longitude Capital Partners Ii, | Major Shareholder | Buy | 215,000 | $15.00 | $3,225,000.00 | | |
| 7/25/2017 | Orbimed Advisors Llc | Insider | Buy | 319,333 | $15.00 | $4,789,995.00 | | |
| 7/25/2017 | Rajeev M Shah | Director | Buy | 533,333 | $15.00 | $7,999,995.00 | | |
| 7/20/2017 | Associates L.L.C. Cdk | Major Shareholder | Buy | 215,000 | $15.00 | $3,225,000.00 | | |
(Data available from 1/1/2013 forward)
Kala Pharmaceuticals (NASDAQ KALA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | -$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter
www.americanbankingnews.com - April 20 at 9:18 PM |
| Brokers Set Expectations for Kala Pharmaceuticals' Q1 2018 Earnings (KALA)
www.americanbankingnews.com - April 20 at 7:10 AM |
| Kala Pharmaceuticals (KALA) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - April 10 at 5:03 PM |
 | Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 10 at 10:55 AM |
| Kala Pharmaceuticals (KALA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 2:01 AM |
| Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
finance.yahoo.com - April 9 at 10:53 AM |
| Kala Pharmaceuticals (KALA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:22 AM |
| Kala Pharmaceuticals (KALA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| Zacks Investment Research Upgrades Kala Pharmaceuticals (KALA) to Hold
www.americanbankingnews.com - April 4 at 6:26 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 3 at 11:18 PM |
| Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
finance.yahoo.com - April 3 at 10:55 AM |
| Short Interest in Kala Pharmaceuticals Inc (KALA) Drops By 21.7%
www.americanbankingnews.com - March 31 at 2:56 AM |
 | Kala Pharmaceuticals 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 28 at 10:37 AM |
| Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 27 at 10:55 AM |
| Kala Pharmaceuticals (KALA) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - March 27 at 7:25 AM |
 | BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
www.reuters.com - March 26 at 11:10 AM |
| Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 26 at 11:10 AM |
| Kala Pharma reports 4Q loss
finance.yahoo.com - March 26 at 11:10 AM |
| Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
finance.yahoo.com - March 19 at 10:45 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - March 17 at 9:10 PM |
| Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 16 at 1:54 AM |
| BRIEF-Kala Pharma Says Increased Size Of Board From 9 To 10
www.reuters.com - March 5 at 10:59 AM |
| Emory University Acquires New Stake in Kala Pharmaceuticals Inc (KALA)
www.americanbankingnews.com - March 4 at 2:59 PM |
| Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 19 at 1:46 AM |
| Kala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 17 at 2:10 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM |
| Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - February 12 at 3:16 AM |
| Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 11 at 9:42 PM |
| Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)
www.americanbankingnews.com - February 4 at 11:08 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in Stock
www.americanbankingnews.com - January 30 at 6:32 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM |
| Kala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 28 at 2:34 AM |
| Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - January 26 at 5:04 AM |
| Kala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & Co
www.americanbankingnews.com - January 26 at 12:22 AM |
| Kala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:40 AM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 Shares
www.americanbankingnews.com - January 24 at 9:08 PM |
| Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of Stock
www.americanbankingnews.com - January 24 at 9:08 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM |
| Kala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in December
www.americanbankingnews.com - January 14 at 2:32 AM |
| Kala Pharmaceuticals (KALA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - January 13 at 3:26 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 Shares
www.americanbankingnews.com - January 12 at 6:26 PM |
| Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 170,338 Shares
www.americanbankingnews.com - January 12 at 6:26 PM |
| BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
www.reuters.com - January 12 at 5:38 PM |
| Kala Pharmaceuticals Inc's (KALA) Lock-Up Period To Expire on January 16th
www.americanbankingnews.com - January 9 at 1:22 AM |
 | Kala Pharmaceuticals (KALA) Reports Mixed Results from Two Phase 3 Trials of KPI-121 0.25% in Dry Eye Disease
www.streetinsider.com - January 5 at 5:34 PM |
 | Kala Pharma shares fall on mixed results from dry eye drug trials
www.nasdaq.com - January 5 at 5:34 PM |
 | UPDATE: Kala shares decline 8% on late-stage trial results for dry eye therapy
www.marketwatch.com - January 5 at 5:34 PM |
| Here's Why Kala Pharmaceuticals Got Crushed on Friday
finance.yahoo.com - January 5 at 5:34 PM |
| Kala Pharmaceuticals' (KALA) Buy Rating Reiterated at Wells Fargo & Co
www.americanbankingnews.com - January 5 at 12:03 PM |
Kala Pharmaceuticals (NASDAQ:KALA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kala Pharmaceuticals (NASDAQ:KALA) Income Statement, Balance Sheet and Cash Flow Statement
Kala Pharmaceuticals (NASDAQ KALA) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
